Genoa Ventures, a San Francisco, CA-based venture firm investing in the convergence of biology and technology, closed its second fund, at $84 million.
Genoa Ventures Fund II will continue Genoa’s investing focus on startups innovating in markets as diverse as research tools, diagnostics, Agri/Food Bio, and industrial bio.
The fund nearly tripled Fund I raised in 2018 while maintaining the early-stage focus and small incremental investing in Seed and Series A companies.
Led by Jenny Rooke, Ph.D., Founder and Managing Director, Genoa invests in early-stage companies working in the convergence of biology and technology to accelerate the pace of innovation, transform industries, and solve some of the most fundamental challenges to life. The firm identifies opportunities early and focuses its investments and expertise to empower the next great category-defining companies.
To date, the team has made nine portfolio investments from Fund II, including Aqtual, a cell-free DNA diagnostics platform; Stemson, personalized hair regeneration based on stem cell technology; Epitel, a first-in-class wireless, 24/7 EEG monitoring for seizures; SimBioSys, enabling informed clinical decision support for cancer patients and their doctors; Meiogenix, developing breeding technologies to address global food and industrial challenges; Redux, developing advanced animal health products; and Codetta, enabling highly multiplexed, quantitative multi-omic analysis of DNA, RNA, and protein.
In addition to Dr. Rooke, Genoa has nine other investment professionals all with advanced degrees in the sciences, including Vikram Chaudhery, Ph.D., who was recently promoted to partner, Bill Hyun, Ph.D., Negin Mokhtari, Ph.D., Dave Summa, Paco Cifuentes, Ph.D., Landon Merrill, Richard Kenny, Tony Day, Ph.D., and Paul Conley, Ph.D.
The firm also has an exclusive partnership with Hawkwood Biotech Partners, a bioindustrial scale-up consultancy, which provides insight and advisory services to Genoa and its portfolio companies.
FinSMEs
29/07/2022